Prognostic Role of Preoperative Duke Pancreatic Monoclonal Antigen Type 2 Levels in Patients with Pancreatic Cancer

Shimizu, Yuji; Sugiura, Teiichi; Ashida, Ryo; Ohgi, Katsuhisa; Yamada, Minoru; Otsuka, Shimpei; Uesaka, Katsuhiko

doi:10.1245/s10434-023-13564-7

Cited by 5 publications

(8 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DUPAN-2 is a monoclonal antibody to Lewis (c); it is converted to Lewis (a) by α -1-3/4 fucosyltransferase, the Lewis enzyme. 9 This marker has an advantage, which can be used irrespective of the Lewis antigen phenotype. 9 , 14 , 15 In Lewis-negative patients, CA19-9 levels are typically not elevated; however, DUPAN-2 accumulates in the serum due to the absence of α -1-3/4 fucosyltransferase.…”

Section: Discussionmentioning

confidence: 99%

“…The most specific and sensitive biomarker for the prognosis of pancreatic ductal adenocarcinoma (PDAC) is the carbohydrate antigen (CA) 19-9. 1 – 9 However, patients with PDAC with a Lewis antigen-negative phenotype secrete very little or no CA19-9. 10 – 13 Therefore, in patients with PDAC with normal CA19-9 values, early-stage PDAC or advanced PDAC without elevation of CA19-9 levels can exist, making it difficult to estimate the malignant potential.…”

mentioning

confidence: 99%

“…To solve this problem, we assumed that the combined use of CA19-9 and Duke pancreatic monoclonal antigen type 2 (DUPAN-2) levels may be useful in estimating the malignant potential in all patients with PDAC, because DUPAN-2 levels do not depend on the Lewis antigen phenotype. 9 , 14 , 15 Only a few previous studies have investigated the combined use of CA19-9 and DUPAN-2, because a few institutions measured DUPAN-2 levels routinely. 9 , 14 However, our institution commenced routine measurements of both CA19-9 and DUPAN-2 in 2005, and this study includes the largest number of cases on this topic.…”

mentioning

confidence: 99%

“… 9 , 14 , 15 Only a few previous studies have investigated the combined use of CA19-9 and DUPAN-2, because a few institutions measured DUPAN-2 levels routinely. 9 , 14 However, our institution commenced routine measurements of both CA19-9 and DUPAN-2 in 2005, and this study includes the largest number of cases on this topic. The most important characteristic of this study is the cutoff values for CA19-9 and DUPAN-2.…”

mentioning

confidence: 99%

“…Several previous reports have demonstrated original institutional cutoff values of CA19-9 and DUPAN-2 to predict the prognosis of PDAC. 9 , 16 , 17 These cutoff values were clinically important in each institution; however, it is unclear which cutoff value is the most appropriate. Whether these values are equally useful in all institutions is also a concern.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Clinical Utility of the Combined Use of CA19-9 and DUPAN-2 in Pancreatic Adenocarcinoma

Sumiyoshi,

Uemura,

Shintakuya

et al. 2024

Ann Surg Oncol

View full text Add to dashboard Cite

Purpose Pancreatic ductal adenocarcinoma (PDAC) patients with normal carbohydrate antigen (CA) 19-9 levels can have early-stage cancer or advanced cancer without elevation of CA19-9 level; estimating their malignant potential is difficult. This study investigated the clinical utility of the combined use of preoperative CA 19-9 and Duke pancreatic monoclonal antigen type 2 (DUPAN-2) levels in patients with PDAC. Methods Patients who underwent curative-intent surgery for PDAC between November 2005 and December 2021 were investigated. Eligible patients were classified into four groups based on these two markers. Among patients with normal CA19-9 levels, those with normal and high DUPAN-2 levels were classified into normal/normal (N/N) and normal/high (N/H) groups, respectively. Among patients with high CA19-9 levels, those with normal and high DUPAN-2 levels were classified into high/normal (H/N) and high/high (H/H) groups, respectively. Survival rates were compared between the groups. Results Among 521 patients, the N/N, N/H, H/N, and H/H groups accounted for 25.0%, 10.6%, 35.1%, and 29.4% of patients, respectively. The proportions of resectable PDAC in the N/N and H/N groups (71.5% and 66.7%) were significantly higher than those in the N/H and H/H groups (49.1% and 54.9%) (P < 0.01). The 5-year survival rates in the N/N, N/H, H/N, and H/H groups were 66.0%, 31.1%, 34.9%, and 29.7%, respectively; the rate in the N/N group was significantly better than those in the other three groups (P < 0.0001, P < 0.0001, and P < 0.0001, respectively). Conclusions Only patients with normal CA19-9 and DUPNA-2 values should be diagnosed with early-stage PDAC.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Clinical Utility of the Combined Use of CA19-9 and DUPAN-2 in Pancreatic Adenocarcinoma

Sumiyoshi,

Uemura,

Shintakuya

et al. 2024

Ann Surg Oncol

View full text Add to dashboard Cite

show abstract

DUPAN-2 in pancreatic cancer: Systematic review and meta-analysis

Gong,

Xuan,

Pang

et al. 2025

Clinica Chimica Acta

View full text Add to dashboard Cite

Establishment and characterization of a novel multidrug-resistant pancreatic ductal adenocarcinoma cell line, PDAC-X1

Yu,

Su,

Miao

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

Drug resistance remains a significant challenge in the treatment of pancreatic cancer. The development of drug-resistant cell lines is crucial to understanding the underlying mechanisms of resistance and developing novel drugs to improve clinical outcomes. Here, a novel pancreatic cancer cell line, PDAC-X1, derived from Chinese patients has been established. PDAC-X1 was characterized by the immune phenotype, biology, genetics, molecular characteristics, and tumorigenicity. In vitro analysis revealed that PDAC-X1 cells exhibited epithelial morphology and cell markers (CK7 and CK19), expressed cancer-associated markers (E-cadherin, Vimentin, Ki-67, CEA, CA19-9), and produced pancreatic cancer-like organs in suspension culture. In vivo analysis showed that PDAC-X1 cells maintained tumorigenicity with a 100% tumor formation rate. This cell line exhibited a complex karyotype, dominated by subtriploid karyotypes. In addition, PDAC-X1 cells exhibited intrinsic multidrug resistance to multiple drugs, including gemcitabine, paclitaxel, 5-fluorouracil, and oxaliplatin. In conclusion, the PDAC-X1 cell line has been established and characterized, representing a useful and valuable preclinical model to study the underlying mechanisms of drug resistance and develop novel drug therapeutics to improve patient outcomes.

show abstract

Prognostic Role of Preoperative Duke Pancreatic Monoclonal Antigen Type 2 Levels in Patients with Pancreatic Cancer

Cited by 5 publications

References 29 publications

Clinical Utility of the Combined Use of CA19-9 and DUPAN-2 in Pancreatic Adenocarcinoma

Clinical Utility of the Combined Use of CA19-9 and DUPAN-2 in Pancreatic Adenocarcinoma

DUPAN-2 in pancreatic cancer: Systematic review and meta-analysis

Establishment and characterization of a novel multidrug-resistant pancreatic ductal adenocarcinoma cell line, PDAC-X1

Contact Info

Product

Resources

About